Paper | Topic | Design | Population | Results | ||
---|---|---|---|---|---|---|
Negrini S et al. [43] | Efficacy of PSSE in AIS short-term | Prospective Controlled Cohort | Treatments | SEAS | UP | 1 year Braced: SEAS 1 = UP 5 (P = 0.07) °C: ↑ SEAS (P < 0.05) Clinical results: SEAS > UP (P < 0.05) |
Patients | 23 | 28 | ||||
Females | 18 | 19 | ||||
Pathology | AIS | |||||
Age | 12.7 ± 2.2 | 12.1 ± 1.1 | ||||
°C | 15.5 ± 5.4° | 14.9 ± 6.0° | ||||
Other | No differences at baseline | |||||
Negrini S et al. [44] | Efficacy of PSSE in AIS short-term | Prospective Controlled Cohort | Treatments | SEAS | UP | 1 year Braced: SEAS 6.1% > UP 25.0% (P < 0.05) °C: SEAS ↑ UP SEAS: 23.5% ↑, 11.8% ↓ (excluded braced) UP: 11.1% ↑, 13.9% ↓ (excluded braced) |
Patients | 35 | 39 | ||||
Females | ||||||
Pathology | AIS | |||||
Age | 12.4 ± 2.2 | |||||
°C | 15.0 ± 6.0° | |||||
Others | No differences at baseline | |||||
Romano M et al. [45] | Efficacy of PSSE in AIS medium term | Prospective Controlled Cohort | Treatments | SEAS | UP | 2 years Braced: SEAS 10% > UP 27.6% (P < 0.05) |
Patients | 20 | 37 | ||||
Females | ||||||
Pathology | AIS | |||||
Age | 12.7 ± 2.2 | 12.19 ± 3 | ||||
°C | 15.3 ± 5.4 | |||||
Others | ATR: 8.9 ± 2.8° | |||||
Romano M et al. [46] | Efficacy of PSSE in AIS 10-20° short-term | Prospective Controlled Cohort | Treatments | SEAS | UP | End of growth (Risser 3) RR UP vs SEAS 1.74 (IC95 1.22-2.26) |
Patients | 101 | 187 | ||||
Females | 190 | |||||
Pathology | AIS | |||||
Age | 0ver 10 years | |||||
°C | curves range 10-20° | |||||
Others | Risser 0–3 ; No differences at baseline | |||||
Negrini S et al. [47] | Efficacy of PSSE in AIS | Prospective Controlled Cohort | Treatments | SEAS | UP NOE | End of Growth (Risser 3) °C - Intent-to-Treat Analysis RR NOE < SEAS 1.51 (IC95 1.21-1.80) (P < 0.05) RR NOE < UP 1.40 (IC95 1.08-1.72) (P < 0.05) RR UP = SEAS (P = NS) TRACE: ↑ SEAS (1.8) (P < 0.05); ↑ UP (1.5) (P < 0.05); SEAS > NOE (P < 0.05) |
Patients | 145 | 148 | ||||
Females | ||||||
Pathology | AIS | |||||
Age | ||||||
°C | ||||||
Others | No differences at baseline | |||||
Negrini S et al. [48] | Efficacy of PSSE in AIS in preparation to bracing | Prospective Controlled Cohort | Treatments | SEAS | UP | First x-ray without brace at 5 months °C: SEAS > UP Clinical results (improvement >5°C, >2° ATR): ↑ SEAS (P < 0.05); ↑ UP (P < 0.05); SEAS > UP (P < 0.05) |
Patients | 110 | |||||
Females | 34 | |||||
Pathology | AIS | |||||
Age | 13.5 ± 2.4 | |||||
°C | 31.1 ± 11.1 | |||||
Other | No differences at baseline | |||||
Zaina F et al. [49] | Efficacy of PSSE in AIS in brace weaning | Prospective Controlled Cohort | Treatments | SEAS UP | DIS NOE | End of treatment °C: ↓ DIS 3.9° (P < 0.05); ↓ NOE 3.1° (P < 0.05). UP > DIS (P < 0.05) |
Patients | 39 | DIS 19 NOE 10 | ||||
Females | ||||||
Pathology | AIS | |||||
Age | 15.1 ± 1.0 | |||||
°C | 22.0 ± 8.0° | |||||
Others | No differences at baseline | |||||
Romano M et al. [50] | Efficacy of PSSE in AIS for balance function short-term | Prospective Controlled Cohort | Treatments | SEAS | NOE NOR | 1 year Balance function: SEAS > NOR > NOE (P < 0.05) |
Patients | 20 | NOE 20 NOR 150 | ||||
Females | ||||||
Pathology | AIS | |||||
Age | ||||||
°C | ||||||
Others | No differences at baseline | |||||
Romano M et al. [51] | Efficacy of PSSE in hyperkyphosis | Prospective Controlled Cohort | Treatments | SEAS | UP | End of growth Outcome: Plumbline distances at C7 and L3 C7: SEAS ↑ 61 ± 12 to 39 ± 11 (P < 0.05); UP ↑ 54 ± 12 to 41 ± 11 (P < 0.05) L3: SEAS ↑ 47 ± 11 to 41 ± 13 (P < 0.05) |
Patients | 18 | 22 | ||||
Females | 21 | |||||
Pathology | Hyperkyphosis | |||||
Age | ||||||
°C | ||||||
Others | No differences at baseline |